APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Remicade (Infliximab) and Biosimilar

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Remicade (Infliximab) and Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174032160320 December 2025177 pages

Choose your research edition.

Industry ResearchRemicade (Infliximab) and Biosimilar Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Remicade (Infliximab) and Biosimilar Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Remicade (Infliximab) and Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Remicade (Infliximab) and Biosimilar Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Remicade (Infliximab) and Biosimilar Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Remicade (Infliximab) and Biosimilar market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Remicade (Infliximab) and Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Remicade (Infliximab) and Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Remicade (Infliximab) and Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Remicade (Infliximab) and Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Remicade (Infliximab) and Biosimilar include J & J, Pfizer, Amgen and Organon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Remicade (Infliximab) and Biosimilar market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Remicade (Infliximab) and Biosimilar and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Remicade (Infliximab) and Biosimilar sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Remicade (Infliximab) and Biosimilar market size, projected growth trends, production technologies, key applications, and end-use industries.

Remicade (Infliximab) and Biosimilar Segment by Company

J & J

Pfizer

Amgen

Organon

Remicade (Infliximab) and Biosimilar Segment by Type

Brand

Biosimilar

Remicade (Infliximab) and Biosimilar Segment by Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn’s Disease

Other

Remicade (Infliximab) and Biosimilar Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Remicade (Infliximab) and Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Remicade (Infliximab) and Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Remicade (Infliximab) and Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Remicade (Infliximab) and Biosimilar market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Remicade (Infliximab) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Remicade (Infliximab) and Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Remicade (Infliximab) and Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Remicade (Infliximab) and Biosimilar Industry Trends Table 2. Remicade (Infliximab) and Biosimilar Industry Drivers Table 3. Remicade (Infliximab) and Biosimilar Industry Opportunities and Challenges Table 4. Remicade (Infliximab) and Biosimilar Industry Restraints Table 5. Global Remicade (Infliximab) and Biosimilar Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Remicade (Infliximab) and Biosimilar Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Manufacturers Table 9. Global Remicade (Infliximab) and Biosimilar Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Remicade (Infliximab) and Biosimilar Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Remicade (Infliximab) and Biosimilar Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Remicade (Infliximab) and Biosimilar Manufacturers, Product Type & Application Table 13. Global Remicade (Infliximab) and Biosimilar Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Remicade (Infliximab) and Biosimilar by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Brand Table 17. Major Manufacturers of Biosimilar Table 18. Global Remicade (Infliximab) and Biosimilar Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Remicade (Infliximab) and Biosimilar Sales by Type (2021-2026) & (K Units) Table 20. Global Remicade (Infliximab) and Biosimilar Sales by Type (2027-2032) & (K Units) Table 21. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2021-2026) Table 22. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2027-2032) Table 23. Global Remicade (Infliximab) and Biosimilar Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Remicade (Infliximab) and Biosimilar Revenue by Type (2021-2026) & (K Units) Table 25. Global Remicade (Infliximab) and Biosimilar Revenue by Type (2027-2032) & (K Units) Table 26. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2021-2026) Table 27. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Ankylosing Spondylitis Table 29. Major Manufacturers of Rheumatoid Arthritis Table 30. Major Manufacturers of Crohn’s Disease Table 31. Major Manufacturers of Other Table 32. Global Remicade (Infliximab) and Biosimilar Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Remicade (Infliximab) and Biosimilar Sales by Application (2021-2026) & (K Units) Table 34. Global Remicade (Infliximab) and Biosimilar Sales by Application (2027-2032) & (K Units) Table 35. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2021-2026) Table 36. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2027-2032) Table 37. Global Remicade (Infliximab) and Biosimilar Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Remicade (Infliximab) and Biosimilar Revenue by Application (2021-2026) & (K Units) Table 39. Global Remicade (Infliximab) and Biosimilar Revenue by Application (2027-2032) & (K Units) Table 40. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2021-2026) Table 41. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2027-2032) Table 42. Global Remicade (Infliximab) and Biosimilar Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Remicade (Infliximab) and Biosimilar Sales by Region (2021-2026) & (K Units) Table 44. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Region (2021-2026) Table 45. Global Remicade (Infliximab) and Biosimilar Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Remicade (Infliximab) and Biosimilar Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Remicade (Infliximab) and Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Remicade (Infliximab) and Biosimilar Sales by Country (2021-2026) & (K Units) Table 49. North America Remicade (Infliximab) and Biosimilar Sales by Country (2027-2032) & (K Units) Table 50. Europe Remicade (Infliximab) and Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Remicade (Infliximab) and Biosimilar Sales by Country (2021-2026) & (K Units) Table 52. Europe Remicade (Infliximab) and Biosimilar Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Remicade (Infliximab) and Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Sales by Country (2027-2032) & (K Units) Table 59. Global Remicade (Infliximab) and Biosimilar Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Remicade (Infliximab) and Biosimilar Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Remicade (Infliximab) and Biosimilar Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Region (2021-2026) Table 63. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Region (2027-2032) Table 64. J & J Company Information Table 65. J & J Business Overview Table 66. J & J Remicade (Infliximab) and Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. J & J Remicade (Infliximab) and Biosimilar Product Portfolio Table 68. J & J Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Remicade (Infliximab) and Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer Remicade (Infliximab) and Biosimilar Product Portfolio Table 73. Pfizer Recent Development Table 74. Amgen Company Information Table 75. Amgen Business Overview Table 76. Amgen Remicade (Infliximab) and Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Amgen Remicade (Infliximab) and Biosimilar Product Portfolio Table 78. Amgen Recent Development Table 79. Organon Company Information Table 80. Organon Business Overview Table 81. Organon Remicade (Infliximab) and Biosimilar Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Organon Remicade (Infliximab) and Biosimilar Product Portfolio Table 83. Organon Recent Development Table 84. Key Raw Materials Table 85. Raw Materials Key Suppliers Table 86. Remicade (Infliximab) and Biosimilar Distributors List Table 87. Remicade (Infliximab) and Biosimilar Customers List Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Remicade (Infliximab) and Biosimilar Product Image Figure 2. Global Remicade (Infliximab) and Biosimilar Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Remicade (Infliximab) and Biosimilar Market Size (2021-2032) & (US$ Million) Figure 4. Global Remicade (Infliximab) and Biosimilar Sales (2021-2032) & (K Units) Figure 5. Global Remicade (Infliximab) and Biosimilar Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Remicade (Infliximab) and Biosimilar Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Brand Image Figure 9. Biosimilar Image Figure 10. Global Remicade (Infliximab) and Biosimilar Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Remicade (Infliximab) and Biosimilar Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2021-2032) Figure 13. Global Remicade (Infliximab) and Biosimilar Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Remicade (Infliximab) and Biosimilar Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2021-2032) Figure 16. Ankylosing Spondylitis Image Figure 17. Rheumatoid Arthritis Image Figure 18. Crohn’s Disease Image Figure 19. Other Image Figure 20. Global Remicade (Infliximab) and Biosimilar Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Remicade (Infliximab) and Biosimilar Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2021-2032) Figure 23. Global Remicade (Infliximab) and Biosimilar Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Remicade (Infliximab) and Biosimilar Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2021-2032) Figure 26. North America Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2021-2032) Figure 28. U.S. Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2021-2032) Figure 33. Germany Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2021-2032) Figure 40. China Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2021-2032) Figure 48. Brazil Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Remicade (Infliximab) and Biosimilar Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Remicade (Infliximab) and Biosimilar Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Remicade (Infliximab) and Biosimilar Revenue (2021-2032) & (US$ Million) Figure 59. North America Remicade (Infliximab) and Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Remicade (Infliximab) and Biosimilar Revenue (2021-2032) & (US$ Million) Figure 61. Europe Remicade (Infliximab) and Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Remicade (Infliximab) and Biosimilar Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Remicade (Infliximab) and Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Remicade (Infliximab) and Biosimilar Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Remicade (Infliximab) and Biosimilar Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Brand
  • Biosimilar
Applications
  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other
Companies covered
  • J & J
  • Pfizer
  • Amgen
  • Organon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Remicade (Infliximab) and Biosimilar Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Remicade (Infliximab) and Biosimilar Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Remicade (Infliximab) and Biosimilar Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Remicade (Infliximab) and Biosimilar Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Remicade (Infliximab) and Biosimilar Market Dynamics
  1. 2.1 Remicade (Infliximab) and Biosimilar Industry Trends
  2. 2.2 Remicade (Infliximab) and Biosimilar Industry Drivers
  3. 2.3 Remicade (Infliximab) and Biosimilar Industry Opportunities and Challenges
  4. 2.4 Remicade (Infliximab) and Biosimilar Industry Restraints
3 Remicade (Infliximab) and Biosimilar Market by Manufacturers
  1. 3.1 Global Remicade (Infliximab) and Biosimilar Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Remicade (Infliximab) and Biosimilar Sales by Manufacturers (2021-2026)
  3. 3.3 Global Remicade (Infliximab) and Biosimilar Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Remicade (Infliximab) and Biosimilar Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Remicade (Infliximab) and Biosimilar Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Remicade (Infliximab) and Biosimilar Manufacturers, Product Type & Application
  7. 3.7 Global Remicade (Infliximab) and Biosimilar Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Remicade (Infliximab) and Biosimilar Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Remicade (Infliximab) and Biosimilar Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Remicade (Infliximab) and Biosimilar Tier 1, Tier 2, and Tier 3
4 Remicade (Infliximab) and Biosimilar Market by Type
  1. 4.1 Remicade (Infliximab) and Biosimilar Type Introduction
  2. 4.1.1 Brand
  3. 4.1.2 Biosimilar
  4. 4.2 Global Remicade (Infliximab) and Biosimilar Sales by Type
  5. 4.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Remicade (Infliximab) and Biosimilar Sales by Type (2021-2032)
  7. 4.2.3 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2021-2032)
  8. 4.3 Global Remicade (Infliximab) and Biosimilar Revenue by Type
  9. 4.3.1 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2021-2032)
  11. 4.3.3 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2021-2032)
5 Remicade (Infliximab) and Biosimilar Market by Application
  1. 5.1 Remicade (Infliximab) and Biosimilar Application Introduction
  2. 5.1.1 Ankylosing Spondylitis
  3. 5.1.2 Rheumatoid Arthritis
  4. 5.1.3 Crohn’s Disease
  5. 5.1.4 Other
  6. 5.2 Global Remicade (Infliximab) and Biosimilar Sales by Application
  7. 5.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Remicade (Infliximab) and Biosimilar Sales by Application (2021-2032)
  9. 5.2.3 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2021-2032)
  10. 5.3 Global Remicade (Infliximab) and Biosimilar Revenue by Application
  11. 5.3.1 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2021-2032)
  13. 5.3.3 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2021-2032)
6 Global Remicade (Infliximab) and Biosimilar Sales by Region
  1. 6.1 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Remicade (Infliximab) and Biosimilar Sales by Region (2021-2032)
  3. 6.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Region (2021-2026)
  4. 6.2.2 Global Remicade (Infliximab) and Biosimilar Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Remicade (Infliximab) and Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Remicade (Infliximab) and Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Remicade (Infliximab) and Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Remicade (Infliximab) and Biosimilar Revenue by Region
  1. 7.1 Global Remicade (Infliximab) and Biosimilar Revenue by Region
  2. 7.1.1 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Remicade (Infliximab) and Biosimilar Revenue by Region (2021-2026)
  4. 7.1.3 Global Remicade (Infliximab) and Biosimilar Revenue by Region (2027-2032)
  5. 7.1.4 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Remicade (Infliximab) and Biosimilar Revenue (2021-2032)
  8. 7.2.2 North America Remicade (Infliximab) and Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Remicade (Infliximab) and Biosimilar Revenue (2021-2032)
  11. 7.3.2 Europe Remicade (Infliximab) and Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Remicade (Infliximab) and Biosimilar Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Remicade (Infliximab) and Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 J & J
  2. 8.1.1 J & J Company Information
  3. 8.1.2 J & J Business Overview
  4. 8.1.3 J & J Remicade (Infliximab) and Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 J & J Remicade (Infliximab) and Biosimilar Product Portfolio
  6. 8.1.5 J & J Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Remicade (Infliximab) and Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Remicade (Infliximab) and Biosimilar Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Remicade (Infliximab) and Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Remicade (Infliximab) and Biosimilar Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Organon
  20. 8.4.1 Organon Company Information
  21. 8.4.2 Organon Business Overview
  22. 8.4.3 Organon Remicade (Infliximab) and Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Organon Remicade (Infliximab) and Biosimilar Product Portfolio
  24. 8.4.5 Organon Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Remicade (Infliximab) and Biosimilar Value Chain Analysis
  2. 9.1.1 Remicade (Infliximab) and Biosimilar Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Remicade (Infliximab) and Biosimilar Production Mode & Process
  6. 9.2 Remicade (Infliximab) and Biosimilar Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Remicade (Infliximab) and Biosimilar Distributors
  9. 9.2.3 Remicade (Infliximab) and Biosimilar Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst